Jane Street Group LLC Sells 132,994 Shares of Xencor, Inc. (NASDAQ:XNCR)

Jane Street Group LLC lessened its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 79.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,437 shares of the biopharmaceutical company's stock after selling 132,994 shares during the quarter. Jane Street Group LLC owned 0.05% of Xencor worth $814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in XNCR. Sterling Capital Management LLC lifted its holdings in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 1,040 shares during the last quarter. KBC Group NV boosted its holdings in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after acquiring an additional 813 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Xencor by 49.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,337 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock valued at $162,000 after purchasing an additional 1,282 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in Xencor by 132.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 4,482 shares in the last quarter.

Insider Buying and Selling at Xencor

In other news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the transaction, the executive vice president now directly owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.76% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on XNCR. Barclays decreased their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a report on Thursday, May 8th. Wall Street Zen lowered Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. William Blair initiated coverage on Xencor in a report on Monday, April 21st. They issued an "outperform" rating on the stock. Wedbush reissued an "outperform" rating and set a $31.00 price objective on shares of Xencor in a report on Wednesday, April 30th. Finally, Wells Fargo & Company decreased their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $29.50.

Xencor Trading Up 1.3%

NASDAQ XNCR traded up $0.10 during trading on Thursday, hitting $7.65. 82,683 shares of the company's stock traded hands, compared to its average volume of 771,916. The stock has a fifty day moving average of $9.34 and a two-hundred day moving average of $16.42. Xencor, Inc. has a 12-month low of $7.16 and a 12-month high of $27.24. The firm has a market cap of $544.10 million, a P/E ratio of -2.39 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.06). The company had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor's revenue for the quarter was up 104.6% on a year-over-year basis. During the same period last year, the firm earned ($1.11) earnings per share. As a group, sell-side analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.